Compare Enveric Biosciences Inc (ENVB) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Annaly Capital Management, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Annaly Capital Management, Inc. trades at $23.41 (market cap $16.97B). The key difference: Annaly Capital Management, Inc. is far larger — about 3189.8× Enveric Biosciences Inc's market cap, and Annaly Capital Management, Inc. pays a 12.95% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NLY | |
|---|---|---|
Market Cap | $5.32M | $16.97B |
Sector | Health | Financials |
52-Week High | $17.40 | $24.40 |
52-Week Low | $1.28 | $19.69 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 12.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
NLY trades at $23.42, up 1.78% with a bullish technical outlook. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, with a high net income margin of 91.17% and a modest P/E of 7.47. Recent news highlights its 13% dividend yield and positive earnings expectations for Q2 2026.
Outlook remains positive with analyst consensus at Buy and a $24.40 price target. Key opportunities include dividend income and earnings growth, but risks involve interest rate sensitivity and high leverage, with debt-to-asset ratio rising to 23.55 in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
